GlassScriptPhysician profile
Luke T Evans
NPI 1205822707
$9,956.46
in general payments reported to CMS, 2019-2025
41 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $650 · 2021: $2,094 · 2022: $1,239 · 2023: $1,490 · 2024: $1,659 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,401.12 | 2019-2025 | |
| Janssen Biotech, INC. | $855.53 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $821.90 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $816.50 | 2019-2025 | Xifaxan, Trulance |
| Inari Medical, INC. | $784.86 | 2021 | |
| Gilead Sciences, INC. | $670.58 | 2019-2025 | |
| Celgene Corporation | $436.23 | 2021-2024 | Zeposia |
| Genzyme Corporation | $385.24 | 2022-2025 | |
| Medtronic, INC. | $370.24 | 2021-2024 | Gi Genius |
| Pfizer INC. | $338.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $301.19 | 2022-2025 | Dupixent |
| Allergan, INC. | $228.12 | 2020 | |
| Madrigal Pharmaceuticals | $156.28 | 2025 | Rezdiffra |
| Lilly USA, LLC | $150.82 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $134.04 | 2024-2025 | Iqirvo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.